brentuximab vedotin

Ligand id: 6772

Name: brentuximab vedotin

No information available.
Summary of Clinical Use
Brentuximab vedotin is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma [5] and systemic anaplastic large cell lymphoma. Several clinical trials are evaluating the combination of brentuximab vedotin with immune checkpoint inhibitors, to assess any synergistic effects as a result of dual targeting. Checkpoint inhibitors being investigated in this way include nivolumab and pembrolizumab (both anti-PD-1), and ipilimumab (anti-CTLA4). Brentuximab vedotin + pembrolizumab (NCT02684292) and brentuximab vedotin + nivolumab (NCT03138499) are both Phase 3 studies in patients with relapsed/refractory classical Hodgkin's lymphoma.

Expanded approvals:
In November 2017, the FDA approved brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, following review of results from the Phase 3 ALCANZA trial (NCT01578499) [2].
Mechanism Of Action and Pharmacodynamic Effects
This drug efficiently delivers a highly cytotoxic drug to a specific set of cells, namely CD30 +ve cancer cells. Upon binding to cell surface antigen the conjugate is rapidly internalised and the cytotoxic portion (MMAE) is cleaved. This then travels to the nucleus where it binds β-tubulin and disrupts microtubule formation, thereby causing cell cycle arrest and subsequent cell death. MMAE seems to only bind to β-tubulin [4], at a similar location to the Vinca domain.
External links